Todd Wallach – Chairman and Chief Executive Officer

With more than 20 years of experience in operations, finance and strategy, Mr. Wallach is a successful life sciences entrepreneur who has helped found companies with a combined market capitalization of over $500 million. Prior to MDI, Mr. Wallach was chief financial officer and a member of the founding management team of specialty pharmaceutical company Aton Pharma, Inc., where his team increased the company’s worldwide product sales from $10 million to $40 million in just two years’ time. He was previously vice president of finance and operations and a member of the founding management team of Acuity Pharmaceuticals, Inc., which was acquired by publicly traded OPKO Health. Earlier in his career, Mr. Wallach was a management consultant at Booz Allen Hamilton. Mr. Wallach received an M.S. in technology management from the Wharton School of Business and the School of Engineering and Applied Science at the University of Pennsylvania, an M.S. in biotechnology from the University of Pennsylvania, an M.B.A. from Rider University, and a B.S. in mechanical engineering from Purdue University.

Aryeh L. Gassel, Ph.D. – Founder and President

Dr. Gassel is the founder and president of MDI, and led the development of the novel patent-pending technologies that serve as the foundation of the Detect-Ready molecular diagnostic tests for the rapid detection of infectious diseases. Previously, he was vice president of business development at Integrated DNA Technologies (IDT), which he helped grow from an 18-employee start-up into the largest supplier of custom DNA synthesis in North America, with 370 employees and over $45 million in revenue. He received a Ph.D. from UHS/ The Chicago Medical School and an M.A. from the University of Chicago.

Robert J. Citron – CFO

Mr. Citron brings MDI over 25 years of experience in financial management, including more than 10 years of advising start-ups through his role as Partner and CFO of Jerusalem Global Ventures, a leading Israeli venture capital fund. He also serves as consulting CFO for a number of independent Israeli biotech and medical start-ups, including Izun Pharmaceuticals and formerly, Chiasma, Inc. Earlier in his career, Mr. Citron was Financial Controller of the Israeli branch of Hanson PLC and served as a public accountant with PricewaterhouseCoopers in Israel and BDO Stoy Hayward in London. He is a certified public accountant in Israel and a Fellow of the ICAEW in the UK. Mr. Citron received an honors degree in accounting and finance from the London School of Economics and Political Science.

David Wilson – Vice President, Commercial Operations, Europe

Mr. Wilson brings MDI 18 years of international experience in business development, marketing and sales management, with a focus on the in vitro diagnostics industry. He was the founder and managing director of Bioscience Business Resources, an agency providing consulting services in Europe for U.S.-based diagnostic manufacturers. Previously, Mr. Wilson held roles of increasing responsibility at Genzyme, ultimately serving as director of business development at Genzyme Diagnostics. Earlier he worked in marketing, sales and business development at Genzyme Diagnostics and Genzyme Molecular Oncology. Prior to Genzyme, Mr. Wilson held marketing and sales positions at Boehringer Mannheim Diagnostics. He is a founder and business team member of South East Health Technologies Alliance (SEHTA), an organization supporting health technologies businesses in the south east of England. Mr. Wilson received an M.B.A. from Open University Business School and a B.S. in biochemistry with microbiology from the University of St. Andrews. He also studied at the University of California, Santa Barbara.

Tzvi Tzubery, Ph.D. – Director of Research and Development

An experienced molecular biologist, Dr. Tzubery began working with MDI as a product development scientist and assumed the role of director of R&D; in 2009. Dr. Tzubery completed his undergraduate, masters and pre-doctoral studies at the Hebrew University, where he earned a Ph.D. in biochemistry, an M.S. degree in biotechnology and a B.S. degree in agricultural sciences.

 

Avraham Harris – Director of QA & Regulatory Affairs

Mr. Harris serves as director of QA & regulatory affairs. He brings over ten years’ experience in the fields of regulatory compliance and clinical research to MDI. His areas of expertise include protocol design and the monitoring and management of Phases I-IIIb for local, multi-center and multi-national clinical trials. Prior to joining MDI, Mr. Harris consulted with a number of small biotech companies, serving as their director of clinical development and regulatory compliance. Previously, Mr. Harris was a senior clinical research associate with the leading contract research organization Parexel. Earlier in his career, he was responsible for overseeing clinical trials at Perio Products. Mr. Harris received a B.S. from Bar Ilan University, Ramat Gan, Israel.

Fredi Kleinman – Director of Production

Mr. Kleinman is director of production at MDI, bringing nearly 25 years of research and production experience. Prior to joining MDI, Mr. Kleinman served as a microbiologist at B.A.S. Ltd., where he directed the microbiology laboratory and helped implement the company’s system for the detection of airborne biological hazards. Previously, he served as analytical laboratory manager of BioArt Ltd., a contract research organization. Prior to BioArt, Mr. Kleinman served as production manager at NutriCognia, Ltd., where he oversaw the production, assembly and quality control of the company’s products. Earlier in his career, Mr. Kleinman held research and production positions of increasing responsibility at several medical diagnostics companies. He received an M.S. in biology and a B.S. in biology from the Technion in Haifa, Israel.